<DOC>
	<DOCNO>NCT00079365</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil gemcitabine , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Fluorouracil may make tumor cell sensitive radiation therapy . Brachytherapy use radioactive material , phosphorus P32 , place directly near tumor kill tumor cell . Combining chemotherapy external-beam radiation therapy brachytherapy may kill tumor cell . PURPOSE : This randomized clinical trial study fluorouracil , gemcitabine , external-beam radiation therapy , brachytherapy use phosphorus P32 see well work compare fluorouracil , gemcitabine , external-beam radiation therapy treat patient locally regionally advanced unresectable adenocarcinoma pancreas ( pancreatic cancer ) .</brief_summary>
	<brief_title>Fluorouracil , External-Beam Radiation Therapy , Gemcitabine With Without Brachytherapy Using Phosphorus P32 Treating Patients With Locally Regionally Advanced Unresectable Adenocarcinoma Pancreas</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare survival patient locally regionally advanced unresectable adenocarcinoma pancreas treat fluorouracil , external beam radiotherapy , gemcitabine v without brachytherapy phosphorus P32 suspension . Secondary - Compare time disease progression , tumor response rate , physical performance patient treat regimen . - Compare safety tolerability regimens patient population . - Compare duration response time treatment failure patient treat regimen . OUTLINE : This randomize study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive phosphorus P32 suspension percutaneously CT guidance day 0 month 1 , 2 , 6 , 7 , 8 . Patients receive fluorouracil IV continuously day 1-5 week 1-6 . Patients concurrently undergo external beam radiotherapy 5 day week week 1-6 . At completion radiotherapy , patient receive gemcitabine IV 30 minute weekly 7 week . After 1-week rest , patient receive gemcitabine IV 30 minute weekly 3 week . Treatment repeat every 28 day . - Arm II : Patients receive fluorouracil gemcitabine undergo external beam radiotherapy arm I . In arm , treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 80 patient ( 40 per treatment arm ) accrue study within 24-30 month .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm pancreatic adenocarcinoma Locally regionally advance disease Unresectable disease define follow : Invasion major vascular structure determine preoperatively CT scan , angiogram , CT portogram intraoperatively surgeon Severe comorbidities preclude operation , congestive heart failure , coronary artery disease , chronic obstructive pulmonary disease Bidimensionally measurable disease CT scan No recurrent disease No previously resect pancreatic cancer No tumor pancreas ductal origin ( e.g. , islet cell tumor , lymphoma , sarcoma ) PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count : ≥ 1,500/mm^3 Platelet count ≥ 50,000/mm^3 Hemoglobin ≥ 10 g/dL Hepatic Bilirubin &lt; 2 time upper limit normal ( ULN ) AST ALT &lt; 5 time ULN Alkaline phosphatase &lt; 5 time ULN Albumin ≥ 2.5 mg/dL Renal Creatinine ≤ 1.5 mg/dL Cardiovascular See Disease Characteristics Pulmonary See Disease Characteristics Other No malignancy within past 5 year except curatively resect basal cell carcinoma skin , carcinoma situ cervix breast , early stage prostate cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy No prior radiotherapy pancreatic adenocarcinoma Surgery See Disease Characteristics Other No prior chromic phosphate P32 suspension ( Phosphocol® ) At least 4 week since prior cytotoxic therapy pancreatic adenocarcinoma At least 4 week since prior investigational antitumoral agent No concurrent investigational agent No concurrent anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>